首页 > 最新文献

Genetics in Medicine最新文献

英文 中文
Critically unwell infants and children with mitochondrial disorders diagnosed by ultra-rapid genomic sequencing. 通过超快速基因组测序诊断出患有线粒体疾病的重症婴幼儿。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-14 DOI: 10.1016/j.gim.2024.101293
Megan Ball, Sophie E Bouffler, Christopher B Barnett, Mary-Louise Freckmann, Matthew F Hunter, Benjamin Kamien, Karin S Kassahn, Sebastian Lunke, Chirag V Patel, Jason Pinner, Tony Roscioli, Sarah A Sandaradura, Hamish S Scott, Tiong Y Tan, Mathew Wallis, Alison G Compton, David R Thorburn, Zornitza Stark, John Christodoulou

Purpose: To characterize the diagnostic and clinical outcomes of a cohort of critically ill infants and children with suspected mitochondrial disorders (MD) undergoing ultra-rapid genomic testing as part of a national program.

Methods: Ultra-rapid genomic sequencing was performed in 454 families (genome sequencing: n=290, exome sequencing +/- mitochondrial DNA sequencing: n=164). In 91 individuals, MD was considered, prompting analysis using an MD virtual gene panel. These individuals were reviewed retrospectively and scored according to modified Nijmegen Mitochondrial Disease Criteria.

Results: A diagnosis was achieved in 47% (43/91) of individuals, 40% (17/43) of whom had an MD. Seven additional individuals in whom an MD was not suspected were diagnosed with an MD following broader analysis. Gene-agnostic analysis led to the discovery of two novel disease genes, with pathogenicity validated through targeted functional studies (CRLS1 and MRPL39). Functional studies enabled diagnosis in another four individuals. Of the 24 individuals ultimately diagnosed with an MD, 79% had a change in management, which included 53% whose care was redirected to palliation.

Conclusion: Ultra-rapid genetic diagnosis of MD in acutely unwell infants and children is critical for guiding decisions about the need for additional investigations and clinical management.

目的:作为一项国家计划的一部分,对一组疑似线粒体疾病(MD)的重症婴幼儿进行超快速基因组检测,以确定其诊断和临床结果:对454个家庭进行了超快速基因组测序(基因组测序:290人,外显子组测序+/-线粒体DNA测序:164人)。有 91 人被认为患有多发性硬化症,这促使他们使用多发性硬化症虚拟基因面板进行分析。对这些患者进行了回顾性分析,并根据修改后的奈梅亨线粒体疾病标准进行评分:结果:47%(43/91)的患者得到诊断,其中 40%(17/43)的患者患有 MD。经过更广泛的分析,另有七名未被怀疑患有多发性骨髓瘤的患者被确诊为多发性骨髓瘤患者。基因诊断分析发现了两个新的疾病基因,并通过针对性的功能研究(CRLS1 和 MRPL39)验证了其致病性。功能研究使另外四名患者得以确诊。在最终确诊为多发性硬化症的 24 人中,79% 的人改变了治疗方法,其中 53% 的人的治疗转为缓解:结论:对病情急剧恶化的婴幼儿进行MD超快速基因诊断,对于指导决定是否需要进行其他检查和临床治疗至关重要。
{"title":"Critically unwell infants and children with mitochondrial disorders diagnosed by ultra-rapid genomic sequencing.","authors":"Megan Ball, Sophie E Bouffler, Christopher B Barnett, Mary-Louise Freckmann, Matthew F Hunter, Benjamin Kamien, Karin S Kassahn, Sebastian Lunke, Chirag V Patel, Jason Pinner, Tony Roscioli, Sarah A Sandaradura, Hamish S Scott, Tiong Y Tan, Mathew Wallis, Alison G Compton, David R Thorburn, Zornitza Stark, John Christodoulou","doi":"10.1016/j.gim.2024.101293","DOIUrl":"https://doi.org/10.1016/j.gim.2024.101293","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize the diagnostic and clinical outcomes of a cohort of critically ill infants and children with suspected mitochondrial disorders (MD) undergoing ultra-rapid genomic testing as part of a national program.</p><p><strong>Methods: </strong>Ultra-rapid genomic sequencing was performed in 454 families (genome sequencing: n=290, exome sequencing +/- mitochondrial DNA sequencing: n=164). In 91 individuals, MD was considered, prompting analysis using an MD virtual gene panel. These individuals were reviewed retrospectively and scored according to modified Nijmegen Mitochondrial Disease Criteria.</p><p><strong>Results: </strong>A diagnosis was achieved in 47% (43/91) of individuals, 40% (17/43) of whom had an MD. Seven additional individuals in whom an MD was not suspected were diagnosed with an MD following broader analysis. Gene-agnostic analysis led to the discovery of two novel disease genes, with pathogenicity validated through targeted functional studies (CRLS1 and MRPL39). Functional studies enabled diagnosis in another four individuals. Of the 24 individuals ultimately diagnosed with an MD, 79% had a change in management, which included 53% whose care was redirected to palliation.</p><p><strong>Conclusion: </strong>Ultra-rapid genetic diagnosis of MD in acutely unwell infants and children is critical for guiding decisions about the need for additional investigations and clinical management.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical factors associated with genetic diagnosis in suspected neurogenetic disorders in a tertiary care clinic. 一家三级医疗诊所对疑似神经遗传疾病进行基因诊断的相关临床因素。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-10 DOI: 10.1016/j.gim.2024.101252
Nicole R Wong, Alexandra Klomhaus, David J Adams, Benjamin N Schneider, Sunil Mehta, Charlotte DiStefano, Rujuta B Wilson, Julian A Martinez-Agosto, Shafali S Jeste, Aaron D Besterman

Purpose: This study aimed to identify phenotypic factors associated with genetic diagnoses in patients with neurodevelopmental disorders and generate a decision tree to assist clinicians in identifying patients most likely to receive a positive result on genetic testing.

Methods: We retrospectively reviewed the charts of 316 patients evaluated in a neurodevelopmental clinic between 2014 and 2019. Patients were categorized based on genetic test results. Analyses were performed to identify variables that discriminate between patients with and without a genetic diagnosis.

Results: Patients with a genetic diagnosis were more likely to be female and have a history of motor delay, hypotonia, congenital heart disease, and early intervention. Classification and regression tree analysis revealed that 75% of patients with motor delay had a genetic diagnosis. In patients without motor delay, hypotonia, age of walking, and age at initial evaluation were important indicators of a genetic diagnosis.

Conclusion: Our findings suggest that motor delay and hypotonia are associated with genetic diagnoses in children with neurodevelopmental disorders. The decision tree highlights patient subsets at greater risk and suggests possible phenotypic screens. Future studies could develop validated decision trees based on phenotypic data to assist clinicians in stratifying patients for genetic testing.

目的:本研究旨在确定与神经发育障碍患者基因诊断相关的表型因素,并生成一个决策树,以帮助临床医生确定最有可能在基因检测中获得阳性结果的患者:我们回顾性地查看了2014年至2019年期间在神经发育诊所接受评估的316名患者的病历。根据基因检测结果对患者进行分类。我们进行了分析,以确定区分基因诊断和非基因诊断患者的变量:结果:有基因诊断的患者更有可能是女性,并有运动迟缓、肌张力低下、先天性心脏病和早期干预的病史。分类和回归树分析显示,75%的运动迟缓患者有遗传诊断。在没有运动迟缓的患者中,肌张力低下、行走年龄和初次评估时的年龄是遗传诊断的重要指标:我们的研究结果表明,运动发育迟缓和肌张力低下与神经发育障碍儿童的基因诊断有关。决策树强调了风险较大的患者亚群,并提出了可能的表型筛查建议。未来的研究可以根据表型数据开发经过验证的决策树,以协助临床医生对患者进行分层,以便进行基因检测。
{"title":"Clinical factors associated with genetic diagnosis in suspected neurogenetic disorders in a tertiary care clinic.","authors":"Nicole R Wong, Alexandra Klomhaus, David J Adams, Benjamin N Schneider, Sunil Mehta, Charlotte DiStefano, Rujuta B Wilson, Julian A Martinez-Agosto, Shafali S Jeste, Aaron D Besterman","doi":"10.1016/j.gim.2024.101252","DOIUrl":"10.1016/j.gim.2024.101252","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify phenotypic factors associated with genetic diagnoses in patients with neurodevelopmental disorders and generate a decision tree to assist clinicians in identifying patients most likely to receive a positive result on genetic testing.</p><p><strong>Methods: </strong>We retrospectively reviewed the charts of 316 patients evaluated in a neurodevelopmental clinic between 2014 and 2019. Patients were categorized based on genetic test results. Analyses were performed to identify variables that discriminate between patients with and without a genetic diagnosis.</p><p><strong>Results: </strong>Patients with a genetic diagnosis were more likely to be female and have a history of motor delay, hypotonia, congenital heart disease, and early intervention. Classification and regression tree analysis revealed that 75% of patients with motor delay had a genetic diagnosis. In patients without motor delay, hypotonia, age of walking, and age at initial evaluation were important indicators of a genetic diagnosis.</p><p><strong>Conclusion: </strong>Our findings suggest that motor delay and hypotonia are associated with genetic diagnoses in children with neurodevelopmental disorders. The decision tree highlights patient subsets at greater risk and suggests possible phenotypic screens. Future studies could develop validated decision trees based on phenotypic data to assist clinicians in stratifying patients for genetic testing.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging Clinical Intuition to Improve Accuracy of Phenotype-Driven Prioritization. 利用临床直觉提高表型驱动优先排序的准确性。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-10 DOI: 10.1016/j.gim.2024.101292
Martha A Beckwith, Daniel Danis, Yasemin Bridges, Julius O B Jacobsen, Damian Smedley, Peter N Robinson

Purpose: Clinical intuition is commonly incorporated into the differential diagnosis as an assessment of the likelihood of candidate diagnoses based either on the patient population being seen in a specific clinic or on the signs and symptoms of the initial presentation. Algorithms to support diagnostic sequencing in individuals with a suspected rare genetic disease do not yet incorporate intuition and instead assume that each Mendelian disease has an equal pretest probability.

Methods: The LIRICAL algorithm calculates the likelihood ratio of clinical manifestations represented by Human Phenotype Ontology (HPO) terms to rank candidate diagnoses. The initial version of LIRICAL assumed an equal pretest probability for each disease in its calculation of the posttest probability (where the test is diagnostic exome or genome sequencing). We introduce Clinical Intuition for Likelihood Ratios (ClintLR), an extension of the LIRICAL algorithm that boosts the pretest probability of groups of related diseases deemed to be more likely.

Results: The average rank of the correct diagnosis in simulations using ClintLR showed a statistically significant improvement over a range of adjustment factors.

Conclusion: ClintLR successfully encodes clinical intuition to improve ranking of rare diseases in diagnostic sequencing. ClintLR is freely available at https://github.com/TheJacksonLaboratory/ClintLR.

目的:临床直觉通常被纳入鉴别诊断中,作为根据特定诊所就诊的患者群体或最初表现的体征和症状对候选诊断可能性的评估。支持对疑似罕见遗传病患者进行诊断测序的算法尚未纳入直觉,而是假定每种孟德尔疾病的检测前概率相同:LIRICAL算法计算人类表型本体(HPO)术语所代表的临床表现的似然比,对候选诊断进行排序。LIRICAL 算法的初始版本在计算检测后概率时假定每种疾病的检测前概率相同(检测为诊断性外显子组或基因组测序)。我们引入了临床直觉似然比(Clinical Intuition for Likelihood Ratios,ClintLR),它是 LIRICAL 算法的扩展,可提高被认为更有可能的相关疾病组的检测前概率:结果:在使用 ClintLR 的模拟实验中,正确诊断的平均等级在一系列调整因素的作用下有显著的统计学改善:结论:ClintLR 成功地编码了临床直觉,提高了诊断测序中罕见病的排序。ClintLR 可在 https://github.com/TheJacksonLaboratory/ClintLR 免费获取。
{"title":"Leveraging Clinical Intuition to Improve Accuracy of Phenotype-Driven Prioritization.","authors":"Martha A Beckwith, Daniel Danis, Yasemin Bridges, Julius O B Jacobsen, Damian Smedley, Peter N Robinson","doi":"10.1016/j.gim.2024.101292","DOIUrl":"https://doi.org/10.1016/j.gim.2024.101292","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical intuition is commonly incorporated into the differential diagnosis as an assessment of the likelihood of candidate diagnoses based either on the patient population being seen in a specific clinic or on the signs and symptoms of the initial presentation. Algorithms to support diagnostic sequencing in individuals with a suspected rare genetic disease do not yet incorporate intuition and instead assume that each Mendelian disease has an equal pretest probability.</p><p><strong>Methods: </strong>The LIRICAL algorithm calculates the likelihood ratio of clinical manifestations represented by Human Phenotype Ontology (HPO) terms to rank candidate diagnoses. The initial version of LIRICAL assumed an equal pretest probability for each disease in its calculation of the posttest probability (where the test is diagnostic exome or genome sequencing). We introduce Clinical Intuition for Likelihood Ratios (ClintLR), an extension of the LIRICAL algorithm that boosts the pretest probability of groups of related diseases deemed to be more likely.</p><p><strong>Results: </strong>The average rank of the correct diagnosis in simulations using ClintLR showed a statistically significant improvement over a range of adjustment factors.</p><p><strong>Conclusion: </strong>ClintLR successfully encodes clinical intuition to improve ranking of rare diseases in diagnostic sequencing. ClintLR is freely available at https://github.com/TheJacksonLaboratory/ClintLR.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Further description of the phenotypic spectrum of neuronal ceroid lipofuscinosis type 11. 进一步描述神经细胞类脂膜脂质沉着病 11 型的表型谱。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-09 DOI: 10.1016/j.gim.2024.101291
Paulo Ribeiro Nóbrega, Anderson Rodrigues Brandão Paiva, Antonio Duarte Amorim Junior, Pedro Lucas Grangeiro Sá Barreto Lima, Katiane Sayão Souza Cabral, Isabella Peixoto Barcelos, André Luis Santos Pessoa, Carlos Frederico Leite Souza-Lima, Matheus Augusto Araújo Castro, Fernando Freua, Emerson de Santana Santos, Margleice Marinho Vieira Rocha, Rayana Elias Maia, Rodrigo Santos Araújo, Juan David Guevara Ramos, Rosane Guazi Resende, Gerson da Silva Carvalho, Luciana Patrizia Andrade Valença, José Ronaldo Lima de Carvalho, Eduardo Sousa Melo, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Henry Houlden, Fernando Kok, David S Lynch

Purpose: Ceroid lipofuscinosis type 11 (CLN11) is a very rare disease, being reported in only 13 unrelated families so far. Further reports are necessary to comprehend the clinical phenotype of this condition. This article aims to report 9 additional cases of CLN11 from 9 unrelated Latin American families presenting with relatively slow disease progression.

Methods: This was a retrospective observational study including patients with CLN11. Patients were identified through an active search for granulin precursor gene (GRN) pathogenic variants across the entire database of next-generation sequencing of a commercial laboratory and by contacting attending physicians to check for clinical and radiologic findings compatible with a neuronal ceroid lipofuscinosis phenotype.

Results: Nine CLN11 patients from unrelated families were evaluated. Age of onset varied between 3 to 17 years. The most common findings were visual impairment, cerebellar ataxia, seizures, myoclonus, and cognitive decline. One patient had a previously unreported finding of cervical, perioral, and tongue myoclonus. Most of the patients were able to walk unassisted after an average of 14.2 years (SD 4.76 y) from disease onset.

Conclusion: We describe 9 new cases of a very rare type of neuronal ceroid lipofuscinosis (CLN11) from Latin America with a recurrent p.(Gln257ProfsTer27) and a novel p.(Cys83Ter) nonsense variant. Our findings suggest that a slowly progressive neuronal ceroid lipofuscinosis might be a clue for the diagnosis of CLN11.

目的:类色素脂褐质沉着病 11 型(CLN11)是一种非常罕见的疾病,迄今为止仅有 13 个无血缘关系的家族报告过这种疾病。要了解这种疾病的临床表型,还需要更多的报道。本文旨在报告另外九例 CLN11 病例,这些病例来自九个无血缘关系的拉美家庭,病情发展相对缓慢:这是一项包括 CLN11 患者在内的回顾性观察研究。通过在一家商业实验室的整个下一代测序(NGS)数据库中搜索GRN致病变体,并联系主治医生检查是否有与神经细胞类脂膜炎表型相符的临床和影像学结果,确定了患者:结果:评估了来自非亲属关系家庭的9名CLN11患者。发病年龄从 3 岁到 17 岁不等。最常见的症状是视力障碍、小脑共济失调、癫痫发作、肌阵挛和认知能力下降。有一名患者出现了颈部、口周和舌肌阵挛,这在以前从未报道过。大多数患者在发病后平均 14.2 年(标准差 4.76 年)就能独立行走:我们描述了九例来自拉丁美洲的神经细胞类脂质硬化症(CLN11)新病例,这些病例均患有复发性p.(Gln257ProfsTer27)和新型p.(Cys83Ter)无义变异。我们的研究结果表明,缓慢进展的 NCL 可能是诊断 CLN11 的线索。
{"title":"Further description of the phenotypic spectrum of neuronal ceroid lipofuscinosis type 11.","authors":"Paulo Ribeiro Nóbrega, Anderson Rodrigues Brandão Paiva, Antonio Duarte Amorim Junior, Pedro Lucas Grangeiro Sá Barreto Lima, Katiane Sayão Souza Cabral, Isabella Peixoto Barcelos, André Luis Santos Pessoa, Carlos Frederico Leite Souza-Lima, Matheus Augusto Araújo Castro, Fernando Freua, Emerson de Santana Santos, Margleice Marinho Vieira Rocha, Rayana Elias Maia, Rodrigo Santos Araújo, Juan David Guevara Ramos, Rosane Guazi Resende, Gerson da Silva Carvalho, Luciana Patrizia Andrade Valença, José Ronaldo Lima de Carvalho, Eduardo Sousa Melo, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Henry Houlden, Fernando Kok, David S Lynch","doi":"10.1016/j.gim.2024.101291","DOIUrl":"10.1016/j.gim.2024.101291","url":null,"abstract":"<p><strong>Purpose: </strong>Ceroid lipofuscinosis type 11 (CLN11) is a very rare disease, being reported in only 13 unrelated families so far. Further reports are necessary to comprehend the clinical phenotype of this condition. This article aims to report 9 additional cases of CLN11 from 9 unrelated Latin American families presenting with relatively slow disease progression.</p><p><strong>Methods: </strong>This was a retrospective observational study including patients with CLN11. Patients were identified through an active search for granulin precursor gene (GRN) pathogenic variants across the entire database of next-generation sequencing of a commercial laboratory and by contacting attending physicians to check for clinical and radiologic findings compatible with a neuronal ceroid lipofuscinosis phenotype.</p><p><strong>Results: </strong>Nine CLN11 patients from unrelated families were evaluated. Age of onset varied between 3 to 17 years. The most common findings were visual impairment, cerebellar ataxia, seizures, myoclonus, and cognitive decline. One patient had a previously unreported finding of cervical, perioral, and tongue myoclonus. Most of the patients were able to walk unassisted after an average of 14.2 years (SD 4.76 y) from disease onset.</p><p><strong>Conclusion: </strong>We describe 9 new cases of a very rare type of neuronal ceroid lipofuscinosis (CLN11) from Latin America with a recurrent p.(Gln257ProfsTer27) and a novel p.(Cys83Ter) nonsense variant. Our findings suggest that a slowly progressive neuronal ceroid lipofuscinosis might be a clue for the diagnosis of CLN11.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation 用于选择基因条件对以纳入新生儿测序面板的系统框架:早期检查实施。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-05 DOI: 10.1016/j.gim.2024.101290

Purpose

Research is underway worldwide to investigate the feasibility, acceptability, and utility of sequencing-based newborn screening. Different methods have been used to select gene-condition pairs for screening, leading to highly inconsistent gene lists across studies.

Methods

Early Check developed and utilized actionability-based frameworks for evaluating gene-condition pairs for inclusion in newborn panels (panel 1-high actionability, panel 2-possible actionability). A previously developed framework, the Age-based Semi Quantitative Metric (ASQM), was adapted. Increasing ASQM scores, with a maximum of 15, suggest greater actionability. Wilcoxon tests were performed to compare panel 1 gene-condition pairs on the Recommended Uniform Screening Panel (RUSP) with non-RUSP pairs.

Results

In our first round of assessment, Early Check identified 178 gene-condition pairs for inclusion in panel 1 and 29 for panel 2. Median ASQM scores of RUSP conditions on panel 1 was 12 (range 4 to 15) and non-RUSP was 13 (range 9 to 15). Median scores for panel 2 was 10 (range 6 to 14).

Conclusion

The Early Check frameworks provide a transparent, semiquantitative, and reproducible methodology for selecting gene-condition pairs for newborn screening sequencing pilot studies that may inform future integration of genomic sequencing into population-level newborn screening. Collaborative efforts among newborn sequencing studies to establish shared criteria is needed to enhance cross-study comparisons.
目的全球正在开展研究,调查基于测序的新生儿筛查的可行性、可接受性和实用性。筛选基因条件对的方法各不相同,导致不同研究的基因列表极不一致:早期检查开发并使用了基于可操作性的框架,用于评估基因条件对是否可纳入新生儿筛查(面板 1 - 高可操作性,面板 2 - 可能的可操作性)。对之前开发的基于年龄的半定量指标(ASQM)框架进行了调整。ASQM 分数越高(最高为 15 分),表明可操作性越强。通过 Wilcoxon 检验对推荐统一筛查组(RUSP)中的第一组基因条件对与非推荐统一筛查组基因条件对进行了比较:结果:在第一轮评估中,Early Check 确定了 178 对基因条件对可纳入面板 1,29 对可纳入面板 2。面板 1 中 RUSP 条件的 ASQM 分值中位数为 12(范围在 4 到 15 之间),非 RUSP 为 13(范围在 9 到 15 之间)。小组 2 的得分中位数为 10(范围为 6 至 14):早期检查框架提供了一种透明、半定量和可重复的方法,用于为新生儿疾病筛查测序试点研究选择基因-条件对,为将来将基因组测序纳入人群水平的新生儿疾病筛查提供参考。新生儿测序研究之间需要合作建立共同的标准,以加强跨研究比较。
{"title":"A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation","authors":"","doi":"10.1016/j.gim.2024.101290","DOIUrl":"10.1016/j.gim.2024.101290","url":null,"abstract":"<div><h3>Purpose</h3><div>Research is underway worldwide to investigate the feasibility, acceptability, and utility of sequencing-based newborn screening. Different methods have been used to select gene-condition pairs for screening, leading to highly inconsistent gene lists across studies.</div></div><div><h3>Methods</h3><div>Early Check developed and utilized actionability-based frameworks for evaluating gene-condition pairs for inclusion in newborn panels (panel 1-high actionability, panel 2-possible actionability). A previously developed framework, the Age-based Semi Quantitative Metric (ASQM), was adapted. Increasing ASQM scores, with a maximum of 15, suggest greater actionability. Wilcoxon tests were performed to compare panel 1 gene-condition pairs on the Recommended Uniform Screening Panel (RUSP) with non-RUSP pairs.</div></div><div><h3>Results</h3><div>In our first round of assessment<strong>,</strong> Early Check identified 178 gene-condition pairs for inclusion in panel 1 and 29 for panel 2. Median ASQM scores of RUSP conditions on panel 1 was 12 (range 4 to 15) and non-RUSP was 13 (range 9 to 15). Median scores for panel 2 was 10 (range 6 to 14).</div></div><div><h3>Conclusion</h3><div>The Early Check frameworks provide a transparent, semiquantitative, and reproducible methodology for selecting gene-condition pairs for newborn screening sequencing pilot studies that may inform future integration of genomic sequencing into population-level newborn screening. Collaborative efforts among newborn sequencing studies to establish shared criteria is needed to enhance cross-study comparisons.</div></div>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of newborn screening for mucopolysaccharidosis type IVA and long-term monitoring in Taiwan 台湾实施新生儿黏多醣症IVA型筛检及长期监测。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-04 DOI: 10.1016/j.gim.2024.101286

Purpose

Mucopolysaccharidosis IVA (MPS IVA) is a rare lysosomal storage disorder arising from a deficiency in N-acetylgalactosamine-6-sulfatase.

Methods

From September 2019 to October 2023, a total of 264,843 Taiwanese newborns underwent screening for MPS IVA using dried blood spots and tandem mass spectrometry.

Results

Among the 95 referred infants, 9 (9%) were confirmed to have MPS IVA (group 1), 18 (19%) were highly suspected to have MPS IVA (group 2), 61 (64%) were identified as heterozygotes of MPS IVA (group 3), and 7 (7%) were determined not to have MPS IVA (group 4). A total of 34 different GALNS (HGNC:4122) gene variants were identified through our MPS IVA newborn screening program. The most prevalent variant was c.857C>T p.(Thr286Met), found in 33 cases (29%), followed by c.953T>G p.(Met318Arg) in 22 cases (19%). Intravenous enzyme replacement therapy was initiated in 5 patients at ages ranging from 0.3 to 1.7 years. The estimated incidence of MPS IVA in this screening program was 3.4 per 100,000 live births.

Conclusion

Because of the progressive nature of MPS IVA, an early diagnosis facilitated by newborn screening and prompt initiation of enzyme replacement therapy before irreversible organ damage occurs may result in improved clinical outcomes.
背景:粘多糖病IVA(MPS IVA)是一种罕见的溶酶体储积症,由N-乙酰半乳糖胺-6-硫酸酯酶(GALNS)缺乏引起:从2019年9月至2023年10月,共有264843名台湾新生儿接受了MPS IVA筛查,筛查采用干血斑和串联质谱法:在95名转诊婴儿中,9人(9%)被确诊为患有MPS IVA(第1组),18人(19%)被高度怀疑患有MPS IVA(第2组),61人(64%)被确定为MPS IVA的杂合子(第3组),7人(7%)被确定为未患有MPS IVA(第4组)。通过我们的 MPS IVA 新生儿筛查项目,共发现了 34 种不同的 GALNS(HGNC:4122)基因变异。最常见的变异是 c.857C>T p.(Thr286Met),有 33 例(29%),其次是 c.953T>G p.(Met318Arg),有 22 例(19%)。五名患者在 0.3 至 1.7 岁时开始接受静脉酶替代疗法(ERT)。在这项筛查计划中,MPS IVA 的估计发病率为每 10 万名活产婴儿中 3.4 例:结论:由于 MPS IVA 具有渐进性,通过新生儿筛查及早诊断,并在出现不可逆转的器官损伤之前及时启动 ERT,可改善临床预后。
{"title":"Implementation of newborn screening for mucopolysaccharidosis type IVA and long-term monitoring in Taiwan","authors":"","doi":"10.1016/j.gim.2024.101286","DOIUrl":"10.1016/j.gim.2024.101286","url":null,"abstract":"<div><h3>Purpose</h3><div>Mucopolysaccharidosis IVA (MPS IVA) is a rare lysosomal storage disorder arising from a deficiency in N-acetylgalactosamine-6-sulfatase.</div></div><div><h3>Methods</h3><div>From September 2019 to October 2023, a total of 264,843 Taiwanese newborns underwent screening for MPS IVA using dried blood spots and tandem mass spectrometry.</div></div><div><h3>Results</h3><div>Among the 95 referred infants, 9 (9%) were confirmed to have MPS IVA (group 1), 18 (19%) were highly suspected to have MPS IVA (group 2), 61 (64%) were identified as heterozygotes of MPS IVA (group 3), and 7 (7%) were determined not to have MPS IVA (group 4). A total of 34 different <em>GALNS</em> (HGNC:4122) gene variants were identified through our MPS IVA newborn screening program. The most prevalent variant was c.857C&gt;T p.(Thr286Met), found in 33 cases (29%), followed by c.953T&gt;G p.(Met318Arg) in 22 cases (19%). Intravenous enzyme replacement therapy was initiated in 5 patients at ages ranging from 0.3 to 1.7 years. The estimated incidence of MPS IVA in this screening program was 3.4 per 100,000 live births.</div></div><div><h3>Conclusion</h3><div>Because of the progressive nature of MPS IVA, an early diagnosis facilitated by newborn screening and prompt initiation of enzyme replacement therapy before irreversible organ damage occurs may result in improved clinical outcomes.</div></div>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). 利用癌症表型的性别特异性,对卵巢高钙型小细胞癌(SCCOHT)的SMARCA4致病变体进行无偏见的渗透性评估。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-02 DOI: 10.1016/j.gim.2024.101287
Isaac Wade, Leora Witkowski, Afrida Ahmed, Charlie F Rowlands, Terri P McVeigh, Marc D Tischkowitz, William D Foulkes, Clare Turnbull

Purpose: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an extremely rare, highly aggressive cancer (mean age of onset, 24 years). Nearly all cases are associated with somatic or germline pathogenic variants (GPVs) in SMARCA4. Early bilateral oophorectomy is recommended for unaffected females with a SMARCA4 GPV. However, the penetrance of SMARCA4 GPVs for SCCOHT is highly uncertain and subject to ascertainment bias.

Methods: Leveraging the early-onset, sex-specific, highly morbid nature of SCCOHT, we hypothesized that the penetrance for SCCOHT could be quantified from the deficit in SMARCA4 GPVs in females compared to males in UK Biobank, a population cohort for which recruitment was restricted to those age 40-69. We also analyzed pedigrees ascertained internationally by the Montreal-based SCCOHT-SMARCA4 Registry.

Results: We observed SMARCA4 GPVs in 8/210,182 (0.0038%) female and 18/179,210 (0.0100%) male participants in UK Biobank (p = 0.028), representing a male:female odds ratio of 2.64 (95%CI 1.09-7.02), implying a penetrance of 62% for SCCOHT (given absence of other SMARCA4-related female-specific early morbid diseases). A deficit of GPVs in females in UK Biobank was also demonstrated for BRCA1 and TP53.

Conclusion: Our findings support bilateral oophorectomy in early adulthood as a rational choice for at-risk females with SMARCA4 GPVs.

目的:高钙血症型卵巢小细胞癌(SCCOHT)是一种极其罕见、侵袭性极强的癌症(平均发病年龄为 24 岁)。几乎所有病例都与 SMARCA4 的体细胞或种系致病变体 (GPV) 有关。建议患有 SMARCA4 GPV 的未受影响女性及早进行双侧输卵管切除术。然而,SMARCA4 GPV对SCCOHT的穿透性还很不确定,并且存在确定偏差:利用 SCCOHT 发病早、性别特异性强、发病率高的特点,我们假设可以通过英国生物库(UK Biobank)中女性与男性相比 SMARCA4 GPV 的缺失情况来量化 SCCOHT 的渗透性。我们还分析了位于蒙特利尔的 SCCOHT-SMARCA4 注册中心在国际上确定的血统:在英国生物库中,我们在8/210,182(0.0038%)名女性参与者和18/179,210(0.0100%)名男性参与者中观察到SMARCA4 GPVs(p = 0.028),男女几率比例为2.64(95%CI 1.09-7.02),这意味着SCCOHT的渗透率为62%(考虑到没有其他与SMARCA4相关的女性特异性早期发病疾病)。在英国生物库中,BRCA1 和 TP53 的女性 GPVs 也有缺陷:我们的研究结果支持在成年早期对患有 SMARCA4 GPV 的高危女性进行双侧输卵管切除术。
{"title":"Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).","authors":"Isaac Wade, Leora Witkowski, Afrida Ahmed, Charlie F Rowlands, Terri P McVeigh, Marc D Tischkowitz, William D Foulkes, Clare Turnbull","doi":"10.1016/j.gim.2024.101287","DOIUrl":"https://doi.org/10.1016/j.gim.2024.101287","url":null,"abstract":"<p><strong>Purpose: </strong>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an extremely rare, highly aggressive cancer (mean age of onset, 24 years). Nearly all cases are associated with somatic or germline pathogenic variants (GPVs) in SMARCA4. Early bilateral oophorectomy is recommended for unaffected females with a SMARCA4 GPV. However, the penetrance of SMARCA4 GPVs for SCCOHT is highly uncertain and subject to ascertainment bias.</p><p><strong>Methods: </strong>Leveraging the early-onset, sex-specific, highly morbid nature of SCCOHT, we hypothesized that the penetrance for SCCOHT could be quantified from the deficit in SMARCA4 GPVs in females compared to males in UK Biobank, a population cohort for which recruitment was restricted to those age 40-69. We also analyzed pedigrees ascertained internationally by the Montreal-based SCCOHT-SMARCA4 Registry.</p><p><strong>Results: </strong>We observed SMARCA4 GPVs in 8/210,182 (0.0038%) female and 18/179,210 (0.0100%) male participants in UK Biobank (p = 0.028), representing a male:female odds ratio of 2.64 (95%CI 1.09-7.02), implying a penetrance of 62% for SCCOHT (given absence of other SMARCA4-related female-specific early morbid diseases). A deficit of GPVs in females in UK Biobank was also demonstrated for BRCA1 and TP53.</p><p><strong>Conclusion: </strong>Our findings support bilateral oophorectomy in early adulthood as a rational choice for at-risk females with SMARCA4 GPVs.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep phenotyping of 11 individuals with pathogenic variants in RNU4-2 reveals a clinically recognizable syndrome 对 11 个具有 RNU4-2 致病变体的个体进行深度表型分析,发现了一种临床上可识别的综合征。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-02 DOI: 10.1016/j.gim.2024.101288

Purpose

Despite ever-increasing knowledge of the genetic etiologies of neurodevelopmental disorders, approximately half remain undiagnosed after exome or genome sequencing. Here, we provide a deep clinical characterization of 11 previously unreported patients with a recently described neurodevelopmental disorder (NDD) due to pathogenic variants in RNU4-2.

Methods

The 11 patients were identified in a pool of 70 patients selected for targeted RNU4-2 sequencing on the basis of their clinical phenotypes from a cohort of 1032 individuals with a NDD and without a prior genetic diagnosis.

Results

The 11 patients were aged between 13 months and 36 years. All patients showed moderate to severe developmental delay and/or intellectual disability. Height and weight were below 10th percentile and most showed microcephaly. In almost 50% of the patients, intrauterine growth retardation was detected. All patients showed a distinctive pattern of dysmorphic features, including hooded upper eyelid and epicanthus, full cheeks, tented philtrum, mouth constantly slightly open with an everted lower lip vermilion, high palate, and profuse drooling. Of 11 patients, 64% also presented with ophthalmological problems (mainly strabismus, nystagmus, and refraction errors) and 64% had musculoskeletal features (joint hypermobility, mild scoliosis, and easy fractures).

Conclusion

This work provides an improved characterization of the phenotypic spectrum of RNU4-2 syndrome across different age groups and demonstrates that thorough clinical assessment of patients with an NDD can be enhanced significantly for this novel syndrome.
目的:尽管人们对神经发育障碍遗传病因的了解不断增加,但在进行外显子组或基因组测序后,仍有约一半的患者未被确诊。在此,我们对 11 名以前未报道过的患者进行了深入的临床特征描述,这些患者最近被描述为神经发育障碍(NDD),其病因是 RNU4-2 中的致病变体:这11名患者是从1032名NDD患者中根据其临床表型挑选出来进行RNU4-2靶向测序的70名患者中确定的:11名患者的年龄在13个月至36岁之间。所有患者均有中度至重度发育迟缓和/或智力障碍。身高和体重均低于第10百分位数,大多数患者出现小头畸形。近50%的患者被检测出宫内发育迟缓。所有患者都表现出明显的畸形特征,包括上眼睑凹陷和上睑外翻、面颊丰满、咽鼓管内陷、嘴巴经常微张且下唇朱砂外翻、上腭过高和大量流口水。在 11 名患者中,64% 的人还伴有眼科问题(主要是斜视、眼球震颤和屈光不正),64% 的人伴有肌肉骨骼特征(关节活动过度、轻度脊柱侧弯、易骨折):这项研究改进了 RNU4-2 综合征在不同年龄段的表型谱特征,并证明对 NDD 患者进行全面的临床评估可显著提高这种新型综合征的诊断率。
{"title":"Deep phenotyping of 11 individuals with pathogenic variants in RNU4-2 reveals a clinically recognizable syndrome","authors":"","doi":"10.1016/j.gim.2024.101288","DOIUrl":"10.1016/j.gim.2024.101288","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite ever-increasing knowledge of the genetic etiologies of neurodevelopmental disorders, approximately half remain undiagnosed after exome or genome sequencing. Here, we provide a deep clinical characterization of 11 previously unreported patients with a recently described neurodevelopmental disorder (NDD) due to pathogenic variants in <em>RNU4-2</em>.</div></div><div><h3>Methods</h3><div>The 11 patients were identified in a pool of 70 patients selected for targeted <em>RNU4-2</em> sequencing on the basis of their clinical phenotypes from a cohort of 1032 individuals with a NDD and without a prior genetic diagnosis.</div></div><div><h3>Results</h3><div>The 11 patients were aged between 13 months and 36 years. All patients showed moderate to severe developmental delay and/or intellectual disability. Height and weight were below 10th percentile and most showed microcephaly. In almost 50% of the patients, intrauterine growth retardation was detected. All patients showed a distinctive pattern of dysmorphic features, including hooded upper eyelid and epicanthus, full cheeks, tented philtrum, mouth constantly slightly open with an everted lower lip vermilion, high palate, and profuse drooling. Of 11 patients, 64% also presented with ophthalmological problems (mainly strabismus, nystagmus, and refraction errors) and 64% had musculoskeletal features (joint hypermobility, mild scoliosis, and easy fractures).</div></div><div><h3>Conclusion</h3><div>This work provides an improved characterization of the phenotypic spectrum of <em>RNU4-2</em> syndrome across different age groups and demonstrates that thorough clinical assessment of patients with an NDD can be enhanced significantly for this novel syndrome.</div></div>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on “Comparison of literature mining tools for variant classification: Through the lens of 50 RYR1 variants” by Wermers et al 关于 "变体分类的文献挖掘工具比较:通过 50 个 RYR1 变异的视角",作者 Wermers 等人。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-01 DOI: 10.1016/j.gim.2024.101208
{"title":"Correspondence on “Comparison of literature mining tools for variant classification: Through the lens of 50 RYR1 variants” by Wermers et al","authors":"","doi":"10.1016/j.gim.2024.101208","DOIUrl":"10.1016/j.gim.2024.101208","url":null,"abstract":"","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Points to consider for providing expert witness testimony for the specialty of medical genetics: A statement of the American College of Medical Genetics and Genomics (ACMG) 为医学遗传学专业提供专家证人证词的注意事项:美国医学遗传学和基因组学院(ACMG)声明。
IF 6.6 1区 医学 Q1 GENETICS & HEREDITY Pub Date : 2024-10-01 DOI: 10.1016/j.gim.2024.101229
{"title":"Points to consider for providing expert witness testimony for the specialty of medical genetics: A statement of the American College of Medical Genetics and Genomics (ACMG)","authors":"","doi":"10.1016/j.gim.2024.101229","DOIUrl":"10.1016/j.gim.2024.101229","url":null,"abstract":"","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Genetics in Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1